Influence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosis

Thrombosis and Haemostasis

Volumn 98, Issue 3, 2007, Pages 621-626

  Vayá, Amparo ^a   Falcó, Cristina ^a   Simó, María ^a   Ferrando, Fernando ^a   Mira, Yolanda ^a   Todoli, José ^a   España, Francisco ^a   Corella, Dolores ^b,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Deep vein thrombosis; Haemorheology; Lipids; Obesity

Indexed keywords

APOLIPOPROTEIN B; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD VISCOSITY; BODY MASS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; HEMATOLOGICAL PARAMETERS; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR;

ADULT; BLOOD VISCOSITY; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN; HEMORHEOLOGY; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OBESITY; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRIGLYCERIDES; VENOUS THROMBOSIS;

EID: 34548685350     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-02-0095     Document Type: Article

References (46)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. The Lancet 1999; 353: 1167-1173.
2. Virchow R. Thrombose und Embolie (1846-1856). Verlag-von Johann Ambrosius Barth, Leipzig, Germany, 1910.
3. Lowe GDO. Thrombosis and hemorheology. In: Clinical Hemorheology. Dordrecht/Boston, Martinus Nijhoff Publishers 1987: 195-226.
4. Lowe GDO. Rheological influences on thrombosis. Baillieres Clin Haematol 1994; 7: 573-589.
5. Balendra R, Rumlev A, Orr M, et al. Blood lipids, coagulation, fibrinolysis and rheology in spontaneous proven deep vein thrombosis. Brit J Haematol 1991; 77 (Suppl 1): 83.
6. Koppensteiner R, Hofmann S, Atteneder M, et al. Blood rheology in acute deep venous thrombosis. Follow up to one year after the acute event under conventional anticoagulant treatment. Clin Hemorheol 1992; 12: 495.
7. Chabanel A, Horellou H, Conard J, et al. Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of post-thrombotic treatment. Brit J Haematol 1994; 88: 174-179.
8. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-722.
9. Mira Y, Vayá A, Martínez M, et al. Hemorheological alterations and hypercoagulable state in deep vein thrombosis. Clin Hemorheol Microcirc 1998; 19: 265-270.
10. Vaya A, Mira Y, Martinez M, et al. Biological risk factors for deep vein thrombosis. Clin Hemorheol Microcirc 2002; 26: 41-53.
11. Alt E, Banyai S, Banyai M, et al. Blood rheology in deep venous trombosis - relation to persistent and transient risk factors. Thromb Res 2002; 107: 101-107.
12. Krieger E, van Der Loo B, Amann-Vesti BR, et al. C-reactive protein and red cell aggregation correlate with late venous function after acute deep venous thrombosis. J Vasc Surg 2004; 40: 644-649.
13. Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913". Arch Intern Med 1999; 159: 1886-1890.
14. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
15. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-1189.
16. Vaya A, Mira Y, Ferrando F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002; 118: 255-259.
17. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-498.
18. Fuchs S, Heyse T, Rudofsky G, et al. Continuous passive motion in the prevention of deep-vein thrombosis: a randomised comparison in trauma patients. J Bone Joint Surg Br 2005; 87: 1117-1122.
19. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154: 164-168.
20. Kawasaki T, Kambayashi J, Ariyoshi H, et al. Hypercholesterolemia as a risk factor for deep vein thrombosis. Thromb Res 1997; 88: 67-73.
21. McColl MD, Sattar N, Ellison J, et al. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000; 11: 225-229.
22. Griffin JH, Fernádez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001; 86: 386-394.
23. Gónzalez-Ordóñez AJ, Ferández-Carreira JM, Fernández-Alvarez CR, et al. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica 2003; 88: 1035-1043.
24. Doggen CJM, Smith NL, Lemaitre RZ, et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970-1975.
25. Deguchi H, Pecheniuk NM, Elias DJ, et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-899.
26. Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 4: 1914-1918.
27. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996; 143: 1257-1265.
28. Guidelines for measurement of blood viscosisty and erythrocyte deformability. International Committee for standarization in Haematology, Expert panel on blood rheology. Clin Hemorheol 1986; 6: 439-453.
29. Jung E, Roggenkamp HG, Schneider R, et al. Das Kapillarschlauch-Plasmaviskosimeter. Ein neues Messgerät zur Quantifizierung der Blutplasmaviskosität. Biomed Tech 1983; 28: 249-252.
30. Schmid-Schönbein H, Volger E, Teitel P, et al. New hemorheological techniques for the routine laboratory. Clin Hemorheol 1983; 2: 93-105.
31. Ruef P, Pöschl JMB, Linderkamp. The rheodyn SSD for measuring erythrocyte deformability. Biorheology 1995; 32: 357-358.
32. Mira Y, Vayá A, Martinez M, et al. Effect of unfractionated sodium heparin at therapeutic doses on the hemorheological parameters of patients with deep vein thrombosis. Clin Hemorheol 1996; 16: 277-284.
33. Da Silva MA, Cardoso L, Geraldes J, et al. Haemorheological and coagulation conditions in patients with acute deep venous thrombosis compared with subjects without vascular disease. Clin Hemorheol 1991; 11: 534.
34. Kenny MW, Meakin M, Stuart J. Methods for removal of leucocytes and platelets prior to study of erythrocyte deformability. Clin Hemorheol 1983; 3: 191-200.
35. Stuart J, Stone PCW, Bareford D, et al. Evaluation of leucocyte removal methods for studies of erythrocyte deformability. Clin Hemorheol 1985; 5: 137-147.
36. Razavian SM, Atger V, Giral M, et al. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemia men. Artherioscl Thromb 1994; 14: 361-366.
37. Ruhenstroth-Bauer G, Hossmer G, Ottl J, et al. Highly significant negative correlations between erythrocyte aggregation value and serum value concentration of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease. European Journal of Clinical Investigation 1987; 17: 275-279.
38. Vayá A, Martinez M, Carmena I, et al. Red blood cell aggregation and primary hyperlipoproteinemia. Thromb Res 1993; 72: 119-126.
39. Koenig W, Sund M, Ernst E, et al. Association between rheology and components of lipoproteins in human blood. Circulation 1992; 85: 2197-2204.
40. Falcó C, Vayá A, Simá M, et al. Influence of fibrinogen levels on erythrocyte aggregation determined with the Myrenne aggregometer and the Sefam erythro-aggregometer. Clin Hemorheol Microcirc 2005; 33: 145-151.
41. Weng X, Roederer GO, Beaulieu R, et al. Contribution of acute-phase proteins and cardiovascular risk factors to erythrocyte aggregation in normolipidaemic and hyperlipidaemic individuals. Thromb Haemost 1998; 80: 903-908.
42. Vayá A, Falcó C, Réganon E, et al. Influence of plasma and erythrocyte factors on red blood cell aggregation in survivors of acute myocardial infarction. Thromb Haemost 2004; 91: 354-359.
43. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
44. Margaglione M, Cappucci G, d'Addedda M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18: 562-567.
45. Woodward M, Lowe GDO, Rumley A, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow Monica Survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. British Journal of Haematology 1997; 97: 785-797.
46. Goodman E, Dolan LM, Morrison JA, et al. Factor analysis of clustered cardiovascular risks in adolescence: obesity is the predominant correlate of risk among youth. Circulation 2005; 19: 1970-1977.